Scarica l'app Stockscreener
26.28
0.50%
0.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ZLAB Giù?
Forum
Previsione
Precedente Chiudi:
$26.23
Aprire:
$26.335
Volume 24 ore:
52,763
Relative Volume:
0.06
Capitalizzazione di mercato:
$2.56B
Reddito:
$322.71M
Utile/perdita netta:
$-298.33M
Rapporto P/E:
-6.4098
EPS:
-4.1
Flusso di cassa netto:
$-218.98M
1 W Prestazione:
-1.16%
1M Prestazione:
-5.86%
6M Prestazione:
+31.73%
1 anno Prestazione:
-3.87%
Intervallo 1D:
$26.15
$26.55
Intervallo di 1 settimana:
$24.85
$29.20
Portata 52W:
$13.48
$36.60
Zai Lab Limited Adr Stock (ZLAB) Company Profile
Nome
Zai Lab Limited Adr
Settore
Industria
Telefono
862161632588
Indirizzo
4560 JINKE ROAD, SHANGHAI
Confronta ZLAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ZLAB | 26.29 | 2.56B | 322.71M | -298.33M | -218.98M | -4.10 |
| VRTX | 446.01 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 736.92 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 587.24 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.28 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.39 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-14 | Iniziato | Morgan Stanley | Overweight |
| 2023-08-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-01-21 | Iniziato | Macquarie | Outperform |
| 2021-10-12 | Iniziato | Bernstein | Mkt Perform |
| 2020-04-28 | Iniziato | Goldman | Buy |
| 2020-04-15 | Iniziato | Guggenheim | Buy |
| 2019-07-12 | Iniziato | BofA/Merrill | Buy |
| 2019-07-05 | Iniziato | Macquarie | Outperform |
| 2019-01-29 | Iniziato | Credit Suisse | Outperform |
| 2018-11-21 | Iniziato | Jefferies | Buy |
| 2018-06-21 | Ripresa | Leerink Partners | Outperform |
| 2018-02-14 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Iniziato | JP Morgan | Neutral |
| 2017-10-16 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Zai Lab Limited Adr Borsa (ZLAB) Ultime notizie
Zai Lab Grants Share Units to Employees - Marketscreener.com
Compared to Estimates, Zai Lab Limited (ZLAB) Q3 Earnings: A Look at Key Metrics - MSN
Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares - BioSpace
ZLABZai Lab Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Zai Lab Raises $230M in Oversubscribed Public Offering of American Depositary Shares | ZLAB Stock News - StockTitan
FY2024 EPS Estimates for Zai Lab Increased by Analyst - Defense World
Zai Lab (NASDAQ:ZLAB) Sees Strong Trading Volume – Here’s What Happened - Defense World
Digital Brands Group Inc (DBGI): Is It Worth A Small Bite At $0.10? - Stocks Register
Thermo Fisher Scientific Inc’s (TMO) Stock Is Harder To Predict Than You Think - Stocks Register
Selling Your MicroAlgo Inc (NASDAQ: MLGO) Stock? Here’s What You Need To Know - Stocks Register
Danaher Corp (DHR): An Important Analyst Insights - Stocks Register
Centerpoint Energy Inc (NYSE: CNP): Blank Check On Growth? - Stocks Register
Do Unitedhealth Group Inc (NYSE: UNH) Provide Stability And Growth? - Stocks Register
Major Improvements In VF Corp (VFC) Stock Need To Be Considered - Stocks Register
A Stock Analysis Of Fortive Corp’s (FTV) - Stocks Register
Dollar Tree Inc’s (DLTR) Stock Is Harder To Predict Than You Think - Stocks Register
BioNTech SE ADR (BNTX): An Important Analyst Insights - Stocks Register
Leerink Partnrs Increases Earnings Estimates for Zai Lab - Defense World
Zai Lab Announces $200M Public Offering at $25.50 per ADS | ZLAB Stock News - StockTitan
Zai Lab Announces Pricing of Public Offering of American Depositary Shares - Business Wire
Zai Lab Launches $200M ADS Offering with Goldman Sachs, Jefferies as Lead Managers | ZLAB Stock News - StockTitan
Zai Lab Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Zai Lab Ltd (ZLAB) Reports Q3 2024 Earnings: EPS Loss of $0.04, Revenue at $101.8 Million, Slightly Misses Estimates - GuruFocus.com
abrdn Life Sciences Investors declares $0.50 dividend - MSN
Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates - Business Wire
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for - GlobeNewswire
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China - Business Wire
Zai Lab (ZLAB) Scheduled to Post Quarterly Earnings on Tuesday - Defense World
Zai Lab Limited (NASDAQ:ZLAB) Shares Sold by Mirae Asset Global Investments Co. Ltd. - MarketBeat
JP Morgan analysts reiterates an Overweight rating for Roku Inc (ROKU) - Knox Daily
Is Patterson Companies Inc (NASDAQ: PDCO) A Suitable Stock For New Investors Today? - Stocks Register
Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China - Business Wire
Zai Lab (NASDAQ:ZLAB) Stock Price Down 3.7% – Here’s What Happened - Defense World
Zai Lab Limited (ZLAB) Moves 14.7% Higher: Will This Strength Last? - MSN
Biopharma operator Zai Lab surges to 16-month high on lung cancer drug trial results - Mugglehead
Trial highlights potential next-gen biologic for lung cancer - Marketscreener.com
Zai Lab (NASDAQ:ZLAB) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat
Zai Lab (NASDAQ:ZLAB) Shares Down 3.7%What's Next? - MarketBeat
Hennion & Walsh Asset Management Inc. Boosts Stake in Zai Lab Limited (NASDAQ:ZLAB) - MarketBeat
Zai Lab stock soars to 52-week high, touches $32.5 - Investing.com India
Citi raises Zai Lab target on promising trial results - Investing.com
This Biotech Leader Just Hit A 16-Month High On An 'Impressive' Test - Investor's Business Daily
Zai Lab (NASDAQ:ZLAB) Hits New 12-Month HighHere's What Happened - MarketBeat
ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer - BioSpace
Zai Lab Announces Participation in November and December Investor Conferences - BioSpace
JPMorgan Chase & Co. Raises Zai Lab (NASDAQ:ZLAB) Price Target to $44.00 - MarketBeat
Zai Lab (NASDAQ:ZLAB) Shares Up 6.5% – Still a Buy? - Defense World
Zai Lab (NASDAQ:ZLAB) Stock Price Up 6.5%Here's What Happened - MarketBeat
Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 - Business Wire
Zai Lab (NASDAQ:ZLAB) Shares Gap UpShould You Buy? - MarketBeat
Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024 - BioSpace
Zai Lab Limited Adr Azioni (ZLAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.42%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):